Evercore ISI Cuts Humana (NYSE:HUM) Price Target to $180.00

Humana (NYSE:HUM) had its price target reduced by Evercore ISI from $260.00 to $180.00 in a report published on Thursday morning,MarketScreener reports.

Several other equities research analysts have also recently weighed in on HUM. Barclays reiterated an “underperformer” rating on shares of Humana in a research note on Monday, January 5th. Guggenheim reduced their price objective on Humana from $312.00 to $252.00 and set a “buy” rating for the company in a research report on Thursday. Truist Financial lowered their price objective on Humana from $300.00 to $285.00 and set a “hold” rating on the stock in a research report on Monday, November 10th. Royal Bank Of Canada cut Humana from an “outperform” rating to a “sector perform” rating and reduced their target price for the stock from $322.00 to $189.00 in a research report on Thursday. Finally, Wells Fargo & Company downgraded shares of Humana from an “overweight” rating to a “cautious” rating in a research note on Wednesday, January 7th. Seven research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $238.29.

Humana Stock Up 2.8%

HUM opened at $183.92 on Thursday. The business has a 50 day moving average of $244.65 and a 200-day moving average of $261.05. The stock has a market capitalization of $22.12 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 2.04 and a beta of 0.44. The company has a current ratio of 2.00, a quick ratio of 2.02 and a debt-to-equity ratio of 0.70. Humana has a 1-year low of $169.61 and a 1-year high of $315.35.

Humana (NYSE:HUM) last released its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating the consensus estimate of ($4.01) by $0.05. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm had revenue of $32.64 billion during the quarter, compared to analysts’ expectations of $32.08 billion. During the same period in the prior year, the company earned ($2.16) EPS. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, sell-side analysts anticipate that Humana will post 16.47 earnings per share for the current year.

Institutional Investors Weigh In On Humana

Several institutional investors and hedge funds have recently made changes to their positions in the company. Montag A & Associates Inc. lifted its holdings in Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after purchasing an additional 94 shares during the last quarter. CoreCap Advisors LLC boosted its holdings in shares of Humana by 54.4% in the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 37 shares in the last quarter. Fideuram Asset Management Ireland dac bought a new stake in Humana during the 4th quarter worth approximately $27,000. Rosenberg Matthew Hamilton increased its holdings in Humana by 136.0% during the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after purchasing an additional 68 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in Humana in the 2nd quarter valued at $32,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

More Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.